Crossmark

Management Impact of Metachronous Oligometastatic Disease Identified on 18F-Fluciclovine (Axumin™) PET/CT in Biochemically Recurrent Prostate Cancer

Published Online: 2022-05-23

Published Print: 2022-12

Authors

Anderson, Redmond-Craig

Velez, Erik M.

Jadvar, Hossein https://orcid.org/0000-0002-9455-2484
Funding

Funding for this research was provided by:

National Institutes of Health (R21-EB017568, P30‐CA014089)
License Information

Text and Data Mining valid from 2022-05-23

Version of Record valid from 2022-05-23
More Information

Article History

Received: 10 March 2022

Revised: 6 May 2022

Accepted: 13 May 2022

First Online: 23 May 2022

Declarations

:

: Dr. Hossein Jadvar declare that he is on the advisory board of Radiomedix, a consultant to Bayer and Blue Earth Diagnostics, and on the speaker’s bureau for Lantheus, all unrelated to this submission. Dr. Redmond-Craig Anderson and Dr. Erik M. Velez declare no conflict of interests or competing interests.

Document is current